Radiolabeled Amyloid Binding Compounds for Alzheimer's Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Alzheimer's disease are inadequate, as they rely on invasive procedures, lack specificity, and only provide palliative effects, failing to effectively halt the progression of the disease, and existing imaging agents have poor brain penetration and specificity.
Innovation Solution
Development of radiolabeled amyloid binding compounds that can traverse the blood-brain barrier, specifically binding to amyloid deposits, allowing for accurate in vivo imaging and potential treatment of neurodegenerative disorders, including Alzheimer's disease, by using compounds with specific radiolabels such as 11C, 13N, 15O, 18F, 123I, 124I, 125I, and 77Br.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (post-mortem tissue studies, brain biopsies) are used, then diagnostic accuracy is improved, but patient safety and ease of operation deteriorate due to invasive procedures
Solution Approach 1:
The patent replaces mechanical/invasive diagnostic methods (brain biopsies, post-mortem tissue studies) with a non-invasive imaging system that uses radiolabeled compounds administered systemically. The diagnostic information is obtained through external imaging (PET/SPECT) rather than physical tissue extraction, eliminating surgical risks while maintaining diagnostic capability
Solution Approach 2:
The patent introduces radiolabeled amyloid binding compounds as intermediaries that travel through the bloodstream to reach brain amyloid deposits. These compounds serve as mediators between the external imaging system and the target pathology, enabling indirect but accurate visualization of amyloid burden without direct tissue sampling
2Ease of operation
If existing imaging agents are used, then non-invasive imaging is achieved, but measurement precision deteriorates due to poor brain penetration and low specificity
Solution Approach 1:
The patent optimizes multiple parameters of the imaging compounds including molecular size, lipophilicity, radiolabel selection, and binding affinity to achieve optimal brain penetration and specificity. By systematically adjusting these chemical and physical parameters, the compounds achieve sufficient blood-brain barrier permeability while maintaining high affinity for amyloid deposits
Solution Approach 2:
The patent employs composite molecular structures combining amyloid-binding moieties (such as beta-amyloid peptide sequences or small molecule ligands) with radiolabels (11C, 18F, 123I). This composite design integrates the targeting function of the binding component with the detectable signal of the radiolabel, achieving both specificity and imaging capability
3Measurement precision
If radiolabeled compounds are developed for specific amyloid binding, then measurement precision is improved, but device complexity increases due to radiolabeling requirements
Solution Approach 1:
The patent incorporates radiolabeling sites directly into the molecular structure during synthesis, preparing the compounds with built-in labeling positions. This preliminary preparation simplifies the final radiolabeling step, as the compounds are already configured to accept specific radionuclides without requiring complex modification procedures
Solution Approach 2:
The patent separates the diagnostic function (amyloid binding) from the detection function (radiolabeling) by using modular molecular designs. The amyloid-binding core structure can be synthesized independently and then combined with various radiolabels, allowing the binding specificity to be developed once and reused with different radionuclides for different imaging applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable safe and specific detection and diagnosis of Alzheimer's disease pre-mortem via in vivo imaging, providing low toxicity and effective binding to amyloid deposits, potentially delaying disease progression by allowing for early intervention.
Implementation Method 1
using compounds with specific radiolabels such as 11C, 13N, 15O, 18F, 123I, 124I, 125I, and 77Br
Implementation Method 2
radiolabeled amyloid binding compounds that can traverse the blood-brain barrier, specifically binding to amyloid deposits
Data Source
AI summary
Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.